Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cyclopharm Limited ( (AU:CYC) ) has shared an update.
Cyclopharm Limited has released its 2025 annual report, outlining its performance, governance, and financial position for the year. The report highlights the continued global expansion and market leadership of its Technegas® lung ventilation imaging product, now sold in 67 countries, reinforcing the company’s standing in specialised diagnostic imaging and its relevance to stakeholders.
The document details standard components such as the chairman’s letter, managing director’s review, directors’ report, and audited consolidated financial statements. Together, these sections provide investors and other stakeholders with a comprehensive view of Cyclopharm’s operational progress in 2025 and its ongoing role as a key player in functional lung imaging technologies.
The most recent analyst rating on (AU:CYC) stock is a Sell with a A$0.68 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is a health technology company specialising in functional lung ventilation imaging, with its proprietary Technegas® product established as a clinical market leader in diagnostic imaging. The company’s technology is now available in 67 countries, underscoring its global reach in advanced respiratory imaging solutions.
Average Trading Volume: 140,307
Technical Sentiment Signal: Sell
Current Market Cap: A$89.39M
Find detailed analytics on CYC stock on TipRanks’ Stock Analysis page.